ABVX.PA - ABIVAX
€13.34 -0.04 (-0.3%)
Updated: 08:44 May 13, 2024 ESTNext Session's AI Forecast
98.78%
Avg. Accuracy (AI)
€14.09
Next Week's AI Forecast
0%
Trend's Accuracy (AI)
€14.03
| Rank (0-100) |
| Rank (0-100) |
| Curr. Week | Curr. Month | Curr. Quarter | Next Quarter | Curr Year | -2.25 | -0.28 | 0.28 | 0.26 | -0.15 |
|---|
CURRENT VOLATILITY RANK
Variation from the lowest to the highest value in a period.
| Curr. Week | Curr. Month | Curr. Quarter | Next Quarter | Curr Year | 2.25 | 1.74 | 2.45 | 2.3 | 2.33 |
|---|
STOCHASTIC METRIC
The STOCHASTIC METRIC shows when a financial asset has moved into an overbought or oversold position.
| Curr. Week | Next Week | Curr. Month | Curr. Quarter | 0% | 0% | 0% | 50% |
|---|
MOVING AVERAGE METRIC
| 5 Sessions | Change 5 Sessions | 20 Sessions | Change 20 Sessions | 50 Sessions | Change 50 Sessions | 200 Sessions | 13.25 | -5.56% | 14.03 | 0% | 14.03 | 21.16% | 11.58 |
|---|
RSI METRIC
| RS Hour | RSI Hour | RS Day | RSI Day | 0.53 | 50 | 0.5 | 34.64 |
|---|
ABIVAX Technical Analysis News
ABIVAX
7-11 boulevard Haussmann
Paris 75009
France
33 1 53 83 09 63
https://www.abivax.com
| Sectors: | Healthcare |
| Industry: | Biotechnology |
| F. Time Employees: | 61 |
Description
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.
Corporate Governance
ABIVAX Société Anonyme’s ISS Governance QualityScore as of May 1, 2024 is 10. The pillar scores are Audit: 10; Board: 9; Shareholder Rights: 7; Compensation: 10.
List of holders with stock participation in ABIVAX.
| Holder Rank | Holder | Shares | Date Reported | % Out | Value |
|---|